Literature DB >> 1309532

Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity.

G Bernhardt1, H Reile, H Birnböck, T Spruss, H Schönenberger.   

Abstract

Conventionally in vitro cytotoxicity assays are performed as single-end-point determinations. To compensate for the diversity of growth rates among different cell lines in this report we describe a computerized kinetic chemosensitivity assay based on quantification of biomass by staining cells with crystal violet. As a prerequisite four human breast cancer cell lines (MDA-MB-231, MCF-7, T-47-D and ZR-75-1) were characterized with regard to oestrogen and progesterone receptor content, modal chromosome number and proliferation kinetics depending on the number of passages in culture. With prolonged time in culture for ZR-75-1 exposed to various concentrations of cisplatinum a dose-related increase in drug effect was observed. Owing to a correction of the T/C values for the initial cell mass (at the time when drug is added) a sharp distinction between cytostatic and cytocidal drug effects becomes obvious in plots of corrected T/C values versus time of incubation. The influence of the untreated control on the corrected T/C values and possible time courses of theoretical inhibition profiles (reflecting cytostatic, transient cytotoxic or cytocidal drug effects as well as development of resistance) and their relationship to the corresponding growth curves of drug-treated cells are discussed. Chemosensitivity assays with diethylstilbestrol dipropionate, tamoxifen, melphalan, cisplatinum, vinblastine, Adriamycin and 5-fluorouracil prove the theoretical considerations to be true for MDA-MB-231, MCF-7, T-47-D and ZR-75-1 human breast cancer cell lines in practice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309532     DOI: 10.1007/bf01192309

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  31 in total

1.  Comparison of in vitro methods to determine drug-induced cell lethality.

Authors:  P R Roper; B Drewinko
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

2.  Quantification of cells cultured on 96-well plates.

Authors:  W Kueng; E Silber; U Eppenberger
Journal:  Anal Biochem       Date:  1989-10       Impact factor: 3.365

3.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

4.  Breast tumor cell lines from pleural effusions.

Authors:  R Cailleau; R Young; M Olivé; W J Reeves
Journal:  J Natl Cancer Inst       Date:  1974-09       Impact factor: 13.506

5.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

6.  Cytogenetic studies of human breast cancer lines: MCF-7 and derived variant sublines.

Authors:  J Whang-Peng; E C Lee; C S Kao-Shan; K Seibert; M Lippman
Journal:  J Natl Cancer Inst       Date:  1983-10       Impact factor: 13.506

7.  Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro.

Authors:  R R Reddel; R L Sutherland
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

8.  Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.

Authors:  E von Angerer; H Birnböck; N Knebel
Journal:  Anticancer Drug Des       Date:  1989-06

9.  Establishment and characterization of three new continuous cell lines derived from human breast carcinomas.

Authors:  L W Engel; N A Young; T S Tralka; M E Lippman; S J O'Brien; M J Joyce
Journal:  Cancer Res       Date:  1978-10       Impact factor: 12.701

10.  [DL-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer.

Authors:  R Müller; R Gust; G Bernhardt; C Keller; H Schönenberger; S Seeber; R Osieka; A Eastman; M Jennerwein
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

View more
  31 in total

1.  Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice.

Authors:  H Kiaris; A V Schally; J L Varga
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

2.  [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes.

Authors:  G Bernhardt; R Gust; H Reile; H D vom Orde; R Müller; C Keller; T Spruss; H Schönenberger; T Burgemeister; A Mannschreck
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.

Authors:  Martina Hubensack; Christine Müller; Peter Höcherl; Stephan Fellner; Thilo Spruss; Günther Bernhardt; Armin Buschauer
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-12       Impact factor: 4.553

4.  4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.

Authors:  K Murakami; T Matsuura; M Sano; A Hashimoto; K Yonekura; R Sakukawa; Y Yamada; I Saiki
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

5.  Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity.

Authors:  Dietmar Gross; Günther Bernhardt; Armin Buschauer
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-31       Impact factor: 4.553

6.  Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.

Authors:  Stephan Fellner; Björn Bauer; David S Miller; Martina Schaffrik; Martina Fankhänel; Thilo Spruss; Günther Bernhardt; Claudia Graeff; Lothar Färber; Harald Gschaidmeier; Armin Buschauer; Gert Fricker
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

7.  Tuning the activity of a short arg-trp antimicrobial Peptide by lipidation of a C- or N-terminal lysine side-chain.

Authors:  H Bauke Albada; Pascal Prochnow; Sandra Bobersky; Sina Langklotz; Patrick Schriek; Julia E Bandow; Nils Metzler-Nolte
Journal:  ACS Med Chem Lett       Date:  2012-09-04       Impact factor: 4.345

8.  Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies.

Authors:  Sabine Schertl; Rolf W Hartmann; Christine Batzl-Hartmann; Thilo Spruss; Anton Maucher; Erwin von Angerer; Claus D Schiller; Martin R Schneider; Ronald Gust; Helmut Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-06       Impact factor: 4.553

9.  [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell line.

Authors:  G Bernhardt; R Gust; H Reile; H D vom Orde; R Müller; C Keller; T Spruss; H Schönenberger; T Burgemeister; A Mannschreck
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

10.  In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation.

Authors:  E Ranza; G Mazzini; A Facoetti; R Nano
Journal:  J Neurooncol       Date:  2009-07-24       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.